Reply to Passamonti et al: ruxolitinib and survival improvement in patients with myelofibrosis
Crossref DOI link: https://doi.org/10.1038/leu.2014.312
Published Online: 2014-11-03
Published Print: 2015-03
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Barosi, G
Gale, R P
Text and Data Mining valid from 2014-11-03
Version of Record valid from 2014-11-03
Article History
First Online: 3 November 2014
Competing interests
: The authors declare no conflict of interest.